Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Panleukopenia Virus, St

Verify with FDA CVM →

134 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
134
Total Reports
35
Deaths Reported
2610.0%
Death Rate

Active Ingredients

Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Panleukopenia Virus, St

Administration Routes

Subcutaneous

Species Affected

Cat 134

Most Affected Breeds

Domestic Shorthair 92
Domestic Longhair 17
Domestic Mediumhair 7
Siamese 4
Cat (other) 3
Cat (unknown) 2
Abyssinian cat 1
Maine Coon 1
Birman (Sacred Birman) 1
Bengal 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 62
Anorexia 34
Vomiting 33
Fever 27
Death 24
Other abnormal test result NOS 24
Weight loss 16
Lack of efficacy (bacteria) - NOS 14
Dehydration 12
Behavioural disorder NOS 10
Ataxia 10
Lack of efficacy - NOS 10

Outcome Breakdown

Ongoing
67 (48.9%)
Recovered/Normal
28 (20.4%)
Died
28 (20.4%)
Outcome Unknown
7 (5.1%)
Euthanized
7 (5.1%)

Data Summary

Metric Value
Total adverse event reports 134
Reports involving death 35
Case-fatality rate (reported events) 2610.0%
Distinct species in reports 1
Distinct breeds in reports 15
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Panleukopenia Virus, St Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 134 adverse event reports referencing Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Panleukopenia Virus, St, including 35 reports in which the animal died — a 2610.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Panleukopenia Virus, St. Reported administration route is Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Panleukopenia Virus, St reports are Cat (134 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (92), Domestic Longhair (17), Domestic Mediumhair (7) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Panleukopenia Virus, St are Lethargy (see also Central nervous system depression in 'Neurological') (62), Anorexia (34), Vomiting (33), Fever (27). Of the 137 reports with a coded outcome, Ongoing is the leading category at 48.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Panleukopenia Virus, St.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial